cover
Contact Name
Ira Oktaviani Rz
Contact Email
ira@pkr.ac.id
Phone
+6285265205563
Journal Mail Official
jpk@pkr.ac.id
Editorial Address
Pusat Penelitian dan Pengabdian kepada Masyarakat, Poltekkes Kemenkes Riau Jl. Melur No. 103, Sukajadi, Pekanbaru, Indonesia Office: (0761)36581 |Fax: (0761) 20656 | Phone: 085265205563
Location
Kota pekanbaru,
Riau
INDONESIA
JPK: Jurnal Proteksi Kesehatan
ISSN : 23028610     EISSN : 27151115     DOI : https://doi.org/10.36929/jpk.v9i1
Core Subject : Health,
Jurnal ini menerbitkan artikel penelitian (research article), di bidang : Ilmu Kesehatan dabn Riset Lingkungan
Articles 242 Documents
Exploration of the Antidiabetic Potential of Kalincuang through In Silico Studies on Inhibition of the Alpha-Glucosidase Enzyme Popi Dani; Armenia Armenia; Nova Syafni
JURNAL PROTEKSI KESEHATAN Vol 15 No 1 (2026): JPK: Jurnal Proteksi Kesehatan
Publisher : Poltekkes Kemenkes Riau

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Diabetes mellitus (DM) is a metabolic disease that can be managed by inhibiting the alpha-glucosidase enzyme, which plays a role in breaking down complex carbohydrates into glucose. This approach is effective in reducing glucose absorption and helping control blood sugar levels. Kalincuang, as a by-product of gambir processing which is rich in flavonoid compounds such as catechin, quercetin, and procyanidin, has the potential to be a natural antidiabetic agent. This study aims to evaluate the potential of active compounds in kalincuang as an alpha-glucosidase enzyme inhibitor in silico using a target protein with PDB ID code: 5ZCD. The results of the analysis showed that three flavonoid compounds, namely Tanariflavanone A (-107.02), Epigallocatechin 3-O-P-coumarate (-104.005), and Procyanidin B1 (-100.215), have good binding energy to the target protein, although still higher than acarbose (-134.568). The conclusion of this study shows that kalincuang has the potential as an inhibitor of the alpha-glucosidase enzyme, although its activity is lower than acarbose. Further research is needed to reveal other mechanisms of action that can support the antidiabetic effects of kalincuang.
Evaluation of Anticoagulant Therapy Based on Therapeutic Target Achievement and Dose Appropriateness in Patients Receiving Anticoagulants Isna Wardaniati; Diana Nazara
JURNAL PROTEKSI KESEHATAN Vol 15 No 1 (2026): JPK: Jurnal Proteksi Kesehatan
Publisher : Poltekkes Kemenkes Riau

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Deep Vein Thromboembolism (DVT) is a form of venous thromboembolism requiring anticoagulant therapy to prevent complications. Treatment effectiveness is assessed through therapeutic target achievement based on Activated Partial Thromboplastin Time (APTT) for heparin, Prothrombin Time/International Normalized Ratio (PT/INR) for warfarin, and dose appropriateness for other anticoagulants. This study aimed to evaluate therapeutic target achievement and dose appropriateness in DVT patients receiving anticoagulant therapy at the Inpatient Unit of X Hospital, Pekanbaru, in 2024. This descriptive observational study used a cross-sectional approach with retrospective medical record data. A total of 45 patients were selected using total sampling. Heparin was the most frequently used anticoagulant (22 patients; 48.89%), followed by warfarin (10; 22.22%), rivaroxaban (5; 11.11%), fondaparinux (5; 11.11%), and enoxaparin (3; 6.67%). Therapeutic targets were achieved by 27 patients (84.38%), while 5 patients (15.62%) did not achieve the target. Regarding dose appropriateness, 8 patients (61.53%) received appropriate doses, while 5 patients (38.46%) received inappropriate doses. In conclusion, most DVT patients achieved therapeutic targets and received appropriate doses. Monitoring APTT, PT/INR, and dose appropriateness remains important to support the effectiveness and safety of anticoagulant therapy.